These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27432009)

  • 1. Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis.
    Buxhofer-Ausch V; Gisslinger B; Schalling M; Gleiss A; Schiefer AI; Müllauer L; Thiele J; Kralovics R; Gisslinger H
    Br J Haematol; 2017 Oct; 179(1):166-169. PubMed ID: 27432009
    [No Abstract]   [Full Text] [Related]  

  • 2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.
    Gowin K; Coakley M; Kosiorek H; Mesa R
    Haematologica; 2016 Oct; 101(10):e405-e406. PubMed ID: 27354022
    [No Abstract]   [Full Text] [Related]  

  • 6. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.
    Schalling M; Gleiss A; Gisslinger B; Wölfler A; Buxhofer-Ausch V; Jeryczynski G; Krauth MT; Simonitsch-Klupp I; Beham-Schmid C; Thiele J; Gisslinger H
    Blood Cancer J; 2017 Dec; 7(12):643. PubMed ID: 29233975
    [No Abstract]   [Full Text] [Related]  

  • 8. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Leukemia; 2008 Jan; 22(1):194-5. PubMed ID: 17625603
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.
    Lussana F; Caberlon S; Pagani C; Kamphuisen PW; Büller HR; Cattaneo M
    Thromb Res; 2009 Sep; 124(4):409-17. PubMed ID: 19299003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
    Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
    Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
    Daly S; Conneally E; Langabeer SE
    Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
    [No Abstract]   [Full Text] [Related]  

  • 12. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia.
    Kamiunten A; Shide K; Kameda T; Ito M; Sekine M; Kubuki Y; Hidaka T; Akizuki K; Tahira Y; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Shimoda H; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Oct; 108(4):411-415. PubMed ID: 29987745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.
    Kjaer L; Holmström MO; Cordua S; Andersen MH; Svane IM; Thomassen M; Kruse TA; Pallisgaard N; Skov V; Hasselbalch HC
    Leuk Lymphoma; 2018 Apr; 59(4):973-977. PubMed ID: 28792253
    [No Abstract]   [Full Text] [Related]  

  • 15. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
    Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
    Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
    Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capricious CALR mutated clones in myeloproliferative neoplasms.
    Haslam K; Conneally E; Langabeer SE
    Blood Cells Mol Dis; 2016 Mar; 57():110-1. PubMed ID: 26777583
    [No Abstract]   [Full Text] [Related]  

  • 18. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
    J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Leukemia; 2013 Oct; 27(10):1953-8. PubMed ID: 23467025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.